EP3805253A4 - Mutant of human papillomavirus type 39 l1 protein - Google Patents
Mutant of human papillomavirus type 39 l1 protein Download PDFInfo
- Publication number
- EP3805253A4 EP3805253A4 EP19815471.8A EP19815471A EP3805253A4 EP 3805253 A4 EP3805253 A4 EP 3805253A4 EP 19815471 A EP19815471 A EP 19815471A EP 3805253 A4 EP3805253 A4 EP 3805253A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- mutant
- protein
- human papillomavirus
- papillomavirus type
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000701824 Human papillomavirus type 39 Species 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810563378 | 2018-06-04 | ||
PCT/CN2019/089988 WO2019233415A1 (en) | 2018-06-04 | 2019-06-04 | Mutant of human papillomavirus type 39 l1 protein |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3805253A1 EP3805253A1 (en) | 2021-04-14 |
EP3805253A4 true EP3805253A4 (en) | 2022-04-06 |
Family
ID=68736443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19815471.8A Pending EP3805253A4 (en) | 2018-06-04 | 2019-06-04 | Mutant of human papillomavirus type 39 l1 protein |
Country Status (7)
Country | Link |
---|---|
US (1) | US11427618B2 (en) |
EP (1) | EP3805253A4 (en) |
JP (2) | JP2021526851A (en) |
KR (1) | KR20210018351A (en) |
CN (1) | CN110551183A (en) |
BR (1) | BR112020024694A2 (en) |
WO (1) | WO2019233415A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113667683B (en) * | 2021-08-25 | 2023-02-10 | 上海博唯生物科技有限公司 | Polynucleotide for expressing HPV39L1, expression vector, host cell and application thereof |
CN114195886B (en) * | 2021-11-12 | 2023-05-23 | 郑州大学 | anti-HPV 39L1 protein monoclonal antibody, preparation and application thereof |
CN116023446A (en) * | 2022-10-28 | 2023-04-28 | 北京康乐卫士生物技术股份有限公司 | Expression of human papilloma virus HPV68L1 protein, viroid particle and preparation method thereof |
CN116041444B (en) * | 2022-12-28 | 2023-10-10 | 北京康乐卫士生物技术股份有限公司 | Expression of human papilloma virus HPV39L1 protein, viroid particle and preparation method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101914139A (en) * | 2010-07-16 | 2010-12-15 | 四川大学 | Human papilloma virus (HPV) capsid protein L1 polypeptide and preparation and application thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981173A (en) * | 1996-02-14 | 1999-11-09 | Institut Pasteur | Genital human papillomavirus type 68a (HPV-68a), related to the potentially oncogenic HPV-39 |
DK2154147T3 (en) * | 2007-04-29 | 2015-12-07 | Beijing Wantai Biological Pharmacy Entpr Co Ltd | Truncated L1 protein of human papillomavirus 16 |
CN101481407A (en) * | 2008-01-07 | 2009-07-15 | 马润林 | Modification sequence of recombinant human mammilla tumor virus L1 capsid protein |
NZ589755A (en) * | 2008-06-09 | 2013-04-26 | Bharat Biotech Int Ltd | Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same |
EP3382011A1 (en) * | 2008-08-08 | 2018-10-03 | Takeda Vaccines, Inc. | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
CN103667319B (en) * | 2012-09-10 | 2017-09-26 | 同济大学 | The trivalent vaccine and its preparation method and purposes of anti-human papilloma virus (anti-HPV) |
CN104164373B (en) * | 2013-05-17 | 2019-04-02 | 北京安百胜生物科技有限公司 | The method for generating HPV68L1 albumen with expressed by Hansenula yeast system |
WO2015196112A1 (en) * | 2014-06-19 | 2015-12-23 | The Regents Of The University Of Colorado, A Body Corporate | Human papilloma virus constructs |
-
2019
- 2019-06-04 US US15/734,715 patent/US11427618B2/en active Active
- 2019-06-04 JP JP2021517892A patent/JP2021526851A/en active Pending
- 2019-06-04 WO PCT/CN2019/089988 patent/WO2019233415A1/en unknown
- 2019-06-04 CN CN201910481225.6A patent/CN110551183A/en active Pending
- 2019-06-04 KR KR1020207038070A patent/KR20210018351A/en not_active Application Discontinuation
- 2019-06-04 EP EP19815471.8A patent/EP3805253A4/en active Pending
- 2019-06-04 BR BR112020024694-8A patent/BR112020024694A2/en unknown
-
2023
- 2023-09-08 JP JP2023146255A patent/JP2023182596A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101914139A (en) * | 2010-07-16 | 2010-12-15 | 四川大学 | Human papilloma virus (HPV) capsid protein L1 polypeptide and preparation and application thereof |
Non-Patent Citations (4)
Title |
---|
BOGERS WILLY M ET AL: "Potent Immune Responses in Rhesus Macaques Induced by Nonviral Delivery of a Self-amplifying RNA Vaccine Expressing HIV Type 1 Envelope With a Cationic Nanoemulsion", THE JOURNAL OF INFECTIOUS DISEASES, INFECTIOUS DISEASES SOCIETY OF AMERICA, US, vol. 211, no. 6, 15 March 2015 (2015-03-15), pages 947 - 955, XP009183529, ISSN: 1537-6613, DOI: 10.1093/INFDIS/JIU522 * |
HERD K A ET AL: "Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 319, no. 2, 20 February 2004 (2004-02-20), pages 237 - 248, XP004491671, ISSN: 0042-6822, DOI: 10.1016/J.VIROL.2003.10.032 * |
PATRIZIA VICI ET AL: "Immunologic treatments for precancerous lesions and uterine cervical cancer", JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, BIOMED CENTRAL LTD, LONDON UK, vol. 33, no. 1, 26 March 2014 (2014-03-26), pages 29, XP021183862, ISSN: 1756-9966, DOI: 10.1186/1756-9966-33-29 * |
See also references of WO2019233415A1 * |
Also Published As
Publication number | Publication date |
---|---|
US11427618B2 (en) | 2022-08-30 |
JP2023182596A (en) | 2023-12-26 |
EP3805253A1 (en) | 2021-04-14 |
JP2021526851A (en) | 2021-10-11 |
KR20210018351A (en) | 2021-02-17 |
CN110551183A (en) | 2019-12-10 |
WO2019233415A1 (en) | 2019-12-12 |
BR112020024694A2 (en) | 2021-03-09 |
US20210198322A1 (en) | 2021-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3805253A4 (en) | Mutant of human papillomavirus type 39 l1 protein | |
EP3636752A4 (en) | Novel hyaluronic acid-hydrolyzing enzyme mutant and pharmaceutical composition comprising same | |
EP3763812A4 (en) | Argonaute protein mutant and use thereof | |
EP3385273A4 (en) | Mutant of human papillomavirus type 58 l1 protein | |
EP3917564A4 (en) | Anti-claudin 18 antibodies and methods of use thereof | |
EP3769739A4 (en) | Walking aid chair | |
EP3385274A4 (en) | Mutant of human papillomavirus type 11 l1 protein | |
EP4031152A4 (en) | Methods and probiotic compositions for the treatment of metabolic diseases and disorders | |
EP3906043A4 (en) | Methods and compositions for the treatment of fabry disease | |
EP3858867A4 (en) | Mutant of l1 protein of human papillomavirus type 51 | |
EP3740576A4 (en) | Therapeutic compositions and methods of making and using the same | |
EP3678701A4 (en) | Therapeutic protein compositions and methods of making and using the same | |
EP4083212A4 (en) | Mutant rsv f protein and use thereof | |
EP3784148A4 (en) | Implants and methods of use and assembly | |
EP3897564A4 (en) | Silk-hyaluronic acid tissue fillers and methods of making and using the same | |
EP3761970A4 (en) | Compositions and methods for the treatment of neurological diseases | |
EP4048298A4 (en) | Preparation and use of therapeutic hydrogels | |
EP3758633A4 (en) | Implants and methods of use and assembly | |
EP3909974A4 (en) | Human hepatocyte growth factor mutant and uses thereof | |
EP3805379A4 (en) | Adh protein family mutant and use thereof | |
EP3749633A4 (en) | Targeting ocular diseases with novel ape1/ref-1 inhibitors | |
EP3636663A4 (en) | Mutant human fgf21 and preparation method and use thereof | |
EP4013445A4 (en) | Therapeutic protein compositions and methods | |
EP3920956A4 (en) | Methods of using glycopolysialylated therapeutic proteins | |
EP3846843A4 (en) | Compositions and methods for the treatment of heart disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20201222 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20220304 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20220228BHEP Ipc: A61K 39/12 20060101ALI20220228BHEP Ipc: C12N 15/11 20060101ALI20220228BHEP Ipc: C07K 14/025 20060101AFI20220228BHEP |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230628 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20240613 |